Full-Time

Patient Support Specialist

Phil

Phil

201-500 employees

Digital platform enabling expedited prescription access

Compensation Overview

$20 - $21/hr

Scottsdale, AZ, USA

Hybrid

Category
Customer Experience & Support (1)
Required Skills
Zendesk
Requirements
  • Minimum 1 year of customer support experience (call center experience is preferred)
  • Minimum 1 year of healthcare experience, preferably in enrollments or insurance
  • Strong attention to detail, with experience in an environment with low/no tolerance for errors
  • Strong phone presence with exemplary customer service skills
  • Strong written comprehension and written communication skills
  • Capable of quickly searching knowledgebase to locate answers
  • Familiar with following complex processes, and navigating multiple software systems during their workday
  • Must have a good understanding of computers, hardware, networks, etc.
  • Adaptable to swift changes
  • Open to giving and receiving feedback graciously and professionally
Responsibilities
  • Be signed into Zendesk, and consistently working in the ticket and phone queues assigned by your team lead.
  • Use your resources in the Zendesk Guide knowledgebase to locate the answers to patient questions, and for process steps to complete work.
  • When unable to locate documentation, ask for support using chat groups in order to provide a timely response to the patient.
  • Minimum performance metrics required after 90 days of work: Obtain 85% or better CSAT ratings, Achieve less than 1% error rate, Complete 10 tickets/calls per hour, Adhere to the published work schedule >94% of the time, Other metrics may be assigned upon management discretion
Desired Qualifications
  • Compensation of USD 20 to 21 per hour

Phil.us offers PhilRx, a digital health platform that streamlines obtaining prescribed medications for patients and helps providers manage care. It coordinates clinicians, payers, and pharmacies through a national dispense network, real-time HIPAA-compliant data, and workflows for prior authorization and formulary access. It stands out by delivering an integrated medication-access workflow along with consulting services and telemedicine, not just software. Its goal is to improve patient adherence and increase insured prescriptions while earning revenue from platform subscriptions, consulting services, and potential per-prescription economics.

Company Size

201-500

Company Stage

Debt Financing

Total Funding

$158.6M

Headquarters

San Francisco, California

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • GLP-1 market expansion via PHIL Direct 2.0 telemedicine platform addresses $100B+ obesity treatment opportunity.
  • 150% YoY net revenue growth in 2024 with 10x prescription volume increase since Series D 2021.
  • $60M K2 HealthVentures growth capital funds AI integration to scale patient acquisition and payer relationships.

What critics are saying

  • CoverMyMeds dominates PA market with 95% HCP adoption, commoditizing Phil's core prior authorization automation.
  • Amazon Pharmacy expands Prime-integrated fulfillment, undercutting Phil's dispense network with faster free delivery.
  • CMS July 2026 FHIR API interoperability mandate eliminates proprietary data moat and prefilling competitive advantage.

What makes Phil unique

  • 90%+ enrollment rates via EHR prefill and mobile-first design versus 30% traditional retail baseline.
  • End-to-end script visibility from ad exposure to dispense with integrated PHIL Direct and Core analytics.
  • 50-state pharmacy network with 98%+ plan coverage ensures in-network routing and lowest patient costs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

5%

2 year growth

2%
Business Wire
Apr 2nd, 2026
Tenpoint Therapeutics partners with PHIL to launch direct-to-patient cash program for YUVEZZI presbyopia therapy

Tenpoint Therapeutics and PHIL Inc. have launched a direct-to-patient cash programme for YUVEZZI, the first FDA-approved dual-agent prescription eye drop for presbyopia treatment. The programme aims to improve access to the therapy through affordable pricing, home delivery and dedicated support. Presbyopia affects nearly 128 million Americans and approximately 2 billion people globally, with many patients going untreated due to high out-of-pocket costs and limited access. The partnership seeks to reduce these barriers and support long-term treatment adherence. YUVEZZI contains carbachol and brimonidine tartrate ophthalmic solution at 2.75%/0.1% concentration. PHIL operates a healthcare technology platform that connects pharmaceutical manufacturers with patients to provide more convenient and affordable medication access.

PharmiWeb.com
Apr 2nd, 2026
Tenpoint Therapeutics Ltd and PHIL partner to launch YUVEZZI(TM) direct-to-patient cash program to make novel presbyopia therapy more accessible and affordable.

Tenpoint Therapeutics Ltd and PHIL partner to launch YUVEZZI(TM) direct-to-patient cash program to make novel presbyopia therapy more accessible and affordable. SCOTTSDALE, Ariz.-(BUSINESS WIRE)-Tenpoint Therapeutics, a leading ophthalmic manufacturer, and PHIL Inc., an all-in-one digital hub and Direct-to-Patient platform, today announced the launch of a Direct-to-Patient (DTP) cash program for YUVEZZI(TM), the first and only dual-agent prescription eye drop FDA-approved for the treatment of presbyopia. Why Direct-to-Patient Access Matters for Presbyopia Patients Access and adherence remain persistent challenges in ophthalmology, where treatments are often underutilized due to a complex patient journey with high affordability barriers. Presbyopia, an ophthalmic condition that affects nearly 128 million Americans and approximately 2 billion people globally, has traditionally seen patients go untreated due to high out-of-pocket costs and limited therapy access (AOA, 2023). The opportunity to help meaningfully improve access to presbyopia therapy for millions of patients has never been greater. Modernizing the Access Journey for YUVEZZI(TM) Tenpoint and PHIL have partnered to launch an innovative DTP program, delivering YUVEZZI(TM) directly to patients through a seamless access experience with affordable, transparent pricing, home delivery, and dedicated support. This groundbreaking partnership reflects our shared commitment to improving how presbyopia patients receive therapy through reducing access barriers, lowering out-of-pocket costs, and supporting long-term treatment adherence for presbyopia patients. "We are excited to partner with Tenpoint Therapeutics as they launch YUVEZZI(TM)- a meaningful leap forward for presbyopia patients across the country. For the 128 million Americans living with this condition, our direct-to-patient program provides a seamless and accessible path to this innovative therapy. This partnership demonstrates what's possible when patient access is a top priority." - Deepak Thomas, CEO & Founder, PHIL About Tenpoint: Tenpoint Therapeutics Ltd. is an ophthalmic pharmaceutical company focused on the commercialization of YUVEZZI(TM)(carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S. and approximately 2 billion people globally.[1,2] By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye. For more information, visit tenpointtherapeutics.com. About PHIL Inc.: PHIL is a healthcare technology platform that partners with pharmaceutical manufacturers to empower patients with more convenient and affordable access to their prescribed medications. Through PHIL's digital hub and direct-to-patient platform, PHIL supports access, affordability, and adherence at scale. For more information, visit phil.us. [1] American Optometric Association Health Policy Institute. New Approaches to Presbyopia. 2023. Accessed November 5, 2025. Available at https://www.aoa.org/AOA/Documents/Advocacy/HPI/presbyopia%20brief%20HPI%20Final.pdf. [2] Fricke TR, Tahhan N, Resnikoff S, et al. Global Prevalence of presbyopia and vision impairment from uncorrected presbyopia: systematic review, meta-analysis and modelling. Ophthalmology. 2018;125(10):1492-9. Editor details. * Company: * Businesswire Last Updated: 02-Apr-2026

FinSMEs
Jul 9th, 2025
Phil Receives $60M Growth Capital Facility from K2 HealthVentures

Phil receives $60M growth capital facility from K2 HealthVentures.

Health Technology Insights
Jul 8th, 2025
Phil Secures $60 Million Growth Capital from K2 HealthVentures to Boost AI Integration

Phil, a leading software-driven pharmaceutical commercialization platform, announced a $60 million growth debt financing from K2 HealthVentures, a healthcare and life sciences-focused investment firm.

PR Newswire
Jul 8th, 2025
Phil Secures $60M for AI Integration

Phil, a pharmaceutical commercialization platform, secured a $60 million growth capital facility from K2 HealthVentures to enhance AI integration and expand customer reach. Since its Series D in 2021, Phil has increased prescription volumes over 10x and achieved 150% year-over-year net revenue growth in 2024. The funding will help Phil improve patient care and access, leveraging its software-driven model to overcome traditional barriers in the pharmaceutical industry.